本文選題：黃連素　切入點(diǎn)：型糖尿病　出處：《中國(guó)中藥雜志》2014年08期 　論文類型：期刊論文

【摘要】：黃連素是中藥黃連的主要活性成分,一直被作為一種抗感染、抗炎癥的藥物用于胃腸道的疾病。近年來(lái),許多研究表明黃連素具有調(diào)控糖脂代謝的作用,而這種活性已經(jīng)被臨床、動(dòng)物以及體外細(xì)胞實(shí)驗(yàn)所證實(shí)。黃連素發(fā)揮治療糖尿病改善胰島素抵抵抗的機(jī)制主要包括:可以改善胰島β細(xì)胞的功能,促進(jìn)胰島素的釋放以及胰島細(xì)胞的再生;具有降低甘油三酯、膽固醇的作用;抑制線粒體的功能,減少能量的產(chǎn)生;可激活A(yù)MPK信號(hào)通路,促進(jìn)糖的代謝;通過(guò)調(diào)控和轉(zhuǎn)錄因子如PPARγ,C/EBPα,SREBP-1c,LXR等的表達(dá),進(jìn)而調(diào)控糖脂代謝;具有抗氧化并抑制還原反應(yīng)的作用,從而抑制機(jī)體內(nèi)的氧化應(yīng)激狀態(tài),干預(yù)糖脂代謝的信號(hào)通路。其作為調(diào)控糖脂代謝的藥物在盡管已經(jīng)從臨床和動(dòng)物實(shí)驗(yàn)獲得大量的支持黃連素具有調(diào)節(jié)糖脂代謝,改善胰島素抵抗?fàn)顟B(tài)的證據(jù),但是,在循證醫(yī)學(xué)的時(shí)代仍然需要大規(guī)模的臨床隨機(jī)實(shí)驗(yàn)來(lái)評(píng)估黃連素對(duì)糖尿病及其并發(fā)癥的療效。
[Abstract]:Berberine, the main active component of Coptis chinensis, has been used as an anti-infective and anti-inflammatory drug for gastrointestinal diseases. In recent years, many studies have shown that berberine can regulate glycolipid metabolism. And this activity has been confirmed by clinical, animal and in vitro cell experiments. The mechanisms of berberine in improving insulin resistance in diabetes mellitus include improving the function of islet 尾 cells. Promoting insulin release and islet cell regeneration; reducing triglyceride and cholesterol; inhibiting mitochondrial function; reducing energy production; activating AMPK signaling pathway; promoting glucose metabolism; By regulating and regulating the expression of PPAR 緯 -C / EBP 偽 -SREBP-1cXR, thus regulating the metabolism of glucose and lipid, it has the function of antioxidation and inhibition of reduction reaction, thereby inhibiting the oxidative stress in the body. The signaling pathway that interferes with glycolipid metabolism. Although berberine has been extensively supported in clinical and animal trials to regulate glycolipid metabolism and improve insulin resistance, it has been used as a drug to regulate glycolipid metabolism. In the age of evidence-based medicine, large-scale randomized trials are still needed to assess the efficacy of berberine in the treatment of diabetes and its complications.
【作者單位】： 黑龍江中醫(yī)藥大學(xué)附屬第一醫(yī)院;
【基金】：黑龍江中醫(yī)藥大學(xué)科研基金項(xiàng)目(201212) 黑龍江中醫(yī)藥大學(xué)博士后流動(dòng)站課題項(xiàng)目(LRB12-407)
【分類號(hào)】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 高志強(qiáng);冷三華;陸付耳;謝美娟;徐麗君;王開(kāi)富;;Effect of Berberine on Expression of Hepatocyte Nuclear Factor-4α in Rats with Fructose-induced Insulin Resistance[J];Journal of Huazhong University of Science and Technology(Medical Sciences);2008年03期

2 ;Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion[J];Acta Pharmacologica Sinica;2004年04期

3 倪艷霞;劉安強(qiáng);高云峰;王衛(wèi)紅;宋亞貴;王麗輝;張玉華;;黃連素治療Ⅱ型糖尿病60例療效觀察及實(shí)驗(yàn)研究[J];中西醫(yī)結(jié)合雜志;1988年12期

4 王樹(shù)海,王文健,汪雪峰,陳偉華;黃芪多糖和小檗堿對(duì)3T3-L1脂肪細(xì)胞糖代謝及細(xì)胞分化的影響[J];中國(guó)中西醫(yī)結(jié)合雜志;2004年10期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陶永,崔星來(lái);中藥加黃連素治療老年Ⅱ型糖尿病60例臨床觀察[J];安徽中醫(yī)臨床雜志;1994年03期

2 華衛(wèi)國(guó),宋菊敏,廖菡,李永方,莫啟忠;黃連素對(duì)糖尿病性神經(jīng)病變大鼠神經(jīng)傳導(dǎo)速度的影響及激素的調(diào)節(jié)[J];標(biāo)記免疫分析與臨床;2001年04期

3 趙志英;;自擬溫陽(yáng)消濁飲加二甲雙胍治療脾腎陽(yáng)虛型代謝綜合征臨床觀察[J];北京中醫(yī)藥;2008年08期

4 龐博;趙進(jìn)喜;王穎輝;傅強(qiáng);;糖尿病清熱解毒治法探討[J];中華中醫(yī)藥雜志;2011年07期

5 白梅;任孟軍;劉忠和;;小檗堿治療非酒精性脂肪肝并血脂紊亂的臨床觀察[J];重慶醫(yī)學(xué);2009年10期

6 胡榮;羅先欽;;中藥對(duì)核轉(zhuǎn)錄因子PPARγ的研究進(jìn)展[J];重慶中草藥研究;2008年02期

7 王曉希;李e，

本文編號(hào)：1608500